A phase 3 study of nivolumab (NIVO), NIVO plus ipilimumab (IPI), or chemotherapy for microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): CheckMate 8HW

被引：10

作者：

Andre, T. ^{[1
]}

Van Cutsem, E. ^{[2
,3
]}

Elez, E. ^{[4
]}

Bennouna, J. ^{[5
]}

de la Fouchardiere, C. ^{[6
]}

Yoshino, T. ^{[7
]}

Jensen, L. ^{[8
]}

Mendez, G. ^{[9
]}

Li, J. ^{[10
]}

Goekkurt, E. ^{[11
,12
]}

Abdullaev, S. ^{[13
]}

Chen, T. ^{[13
]}

Lei, M. ^{[13
]}

Lonardi, S. ^{[14
]}

机构：

[1] Hop St Antoine, Paris, France

[2] Univ Hosp Gasthuisberg, Leuven, Belgium

[3] Univ Leuven, Leuven, Belgium

[4] Vall dHebron Inst Oncol, Barcelona, Spain

[5] Univ Hosp Nantes, Nantes, France

[6] Ctr Leon Berard, Lyon, France

[7] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[8] Univ Hosp Southern Denmark, Vejle Hosp, Vejle, Denmark

[9] Fdn Favaloro, Buenos Aires, DF, Argentina

[10] Shanghai East Hosp, Shanghai, Peoples R China

[11] Hematol Oncol Practice Eppendorf HOPE, Hamburg, Germany

[12] Univ Canc Ctr Hamburg UCCH, Hamburg, Germany

[13] Bristol Myers Squibb, Princeton, NJ USA

[14] Veneto Inst Oncol IRCCS, Med Oncol, Padua, Italy

来源：

关键词：

D O I：

10.1016/j.annonc.2022.04.104

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-12

引用

页码：S250 / S250

页数：1